• P A Filho, A Rapoport, V A Alves, O V Denardin, J Sobrinho, and M B Carvalho.
• Hospital Heliópolis, São Paulo, Brazil.
• Sao Paulo Med J. 2001 May 3; 119 (3): 114118114-8.

ContextProtein marker positivity can assist in the definition of the therapeutic approach towards head and neck paragangliomas. The establishment of the therapeutic approach should incorporate the results of such an investigation.ObjectiveTo establish criteria for benignity and malignancy of vagal and jugular-tympanic paragangliomas, via the study of the relationships of sex, age, tumor size, duration of complaints, site, family history, presence of metastases, treatment, histological architecture and cell type with the immunohistochemical reactions to S100 protein, chromogranin and AgKi67.DesignA retrospective study of histological and clinical records.SettingThe Heliópolis and Oswaldo Cruz tertiary general hospitals, São Paulo.Sample8 cases of head and neck paragangliomas.Main MeasurementsDetermination of degree of positivity to paragangliomas via immunohistochemical reactions.Results1). The protein markers for the principal cells (AgKi67 and chromogranin) were sensitive in 100% of the tumors when used together. 2). S100 protein was well identified in the cytoplasm and nucleus of sustentacular cells and underwent reduction in the neoplasias.ConclusionsChromogranin was proven to be a generic marker for neuroendocrine tumors; S100 protein was positive in all 8 cases and the AgKi67 had low positivity in all cases.

24 keywords...

hide…